Christos Chatziantoniou
Inventor
Stats
- 1 US patents issued
- 6 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 1 US Patents Issued
- 6 US Applications Filed
- 4 Total Citation Count
- Nov 17, 2016 Most Recent Filing
- May 18, 2012 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | 1
| 2013
|
| INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 1
1 | 2013
2016 |
| Institut National de Ia Sante et de la Recherche Medicale (INSERM) | 1
| 2012
|
| ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | 1
| 2016
|
| FONDAZIONE IRCCS CA' GRANDA-OSPEDALE MAGGIORE POLICLINICO | 1
| 2015
|
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | 2
1 1 2 | 2012
2013 2015 2016 |
| UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) | 1
| 2015
|
| ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) | 1
| 2015
|
Inventor Addresses
| Address | Duration |
|---|---|
| Paris, FR | Mar 20, 14 - Mar 27, 18 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| C07K: | PEPTIDES | 4 |
| C12N: | MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF | 4 |
| G01N: | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES | 2 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 9926562 | 2018 | Methods for preventing and treating chronic kidney disease (CKD) | 1 |
| 2017/0160,290 | 2017 | A NEW BIOMARKER OF CHRONIC ALLOGRAFT NEPHROPATHY AND OF RENAL TRANSPLANT REJECTION | 0 |
| 2017/0067,053 | 2017 | METHODS FOR PREVENTING AND TREATING CHRONIC KIDNEY DISEASE (CKD) | 2 |
| 2016/0304,881 | 2016 | DDR1 ANTAGONIST OR AN INHIBITOR OF DDR1 GENE EXPRESSION FOR USE IN THE PREVENTION OR TREATMENT OF CRESCENTIC GLOMERULONEPHRITIS | 0 |
| 2015/0184,155 | 2015 | METHODS FOR PREVENTING AND TREATING CHRONIC KIDNEY DISEASE (CKD) | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.